Nature Communications (Jan 2021)

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

  • Chao Zhang,
  • Yifan Wang,
  • Yuanfei Zhu,
  • Caixuan Liu,
  • Chenjian Gu,
  • Shiqi Xu,
  • Yalei Wang,
  • Yu Zhou,
  • Yanxing Wang,
  • Wenyu Han,
  • Xiaoyu Hong,
  • Yong Yang,
  • Xueyang Zhang,
  • Tingfeng Wang,
  • Cong Xu,
  • Qin Hong,
  • Shutian Wang,
  • Qiaoyu Zhao,
  • Weihua Qiao,
  • Jinkai Zang,
  • Liangliang Kong,
  • Fangfang Wang,
  • Haikun Wang,
  • Di Qu,
  • Dimitri Lavillette,
  • Hong Tang,
  • Qiang Deng,
  • Youhua Xie,
  • Yao Cong,
  • Zhong Huang

DOI
https://doi.org/10.1038/s41467-020-20465-w
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 16

Abstract

Read online

Here, the authors identify and characterize two mouse-derived monoclonal antibodies against SARS-CoV-2 spike protein that target different epitopes in RBD and block the interaction S/ACE2 and show that a formulated humanized version cocktail exhibits prophylaxis and therapeutic antiviral effects in an hACE2-adenovector expressed mouse model.